Bucindolol Decreases Atrial Fibrillation Burden in Patients With Heart Failure and the ADRB1 Arg389Arg Genotype

Circ Arrhythm Electrophysiol. 2021 Aug;14(8):e009591. doi: 10.1161/CIRCEP.120.009591. Epub 2021 Jul 16.

Authors

Jonathan P Piccini¹, Christopher Dufton², Ian A Carroll², Jeff S Healey³, William T Abraham⁴, Yaariv Khaykin⁵, Ryan Aleong⁶, Steven K Krueger⁷, William H Sauer⁸, Stephen B Wilton⁹, Michiel Rienstra¹⁰, Dirk J van Veldhuisen¹⁰, Inder S Anand¹¹, Michel White¹², A John Camm¹³, Paul D Ziegler¹⁴, Debra Marshall², Michael R Bristow^{2

6}, Stuart J Connolly³; Genotype-Directed Comparative Effectiveness Trial of Bucindolol and Toprol-XL for Prevention of Atrial Fibrillation/Atrial Flutter in Patients with Heart Failure Trial Investigators*

Collaborators

Genotype-Directed Comparative Effectiveness Trial of Bucindolol and Toprol-XL for Prevention of Atrial Fibrillation/Atrial Flutter in Patients with Heart Failure Trial Investigators*:
F Ayala-Paredes, A Bakbak, M L Bernier, D H Birnie, B Coutu, E Crystal, M W Deyell, K M Dyrda, M C Hartleib, Z W Laksman, P Leong-Sit, C A Morillo, A S Pandey, F Philippon, S Vizel, P Andréka, Z Csanadi, G Z Duray, T Forster, G Kerkovits, B Merkely, A C Nagy, T Simor, D Czarnecka, J D Kasprzak, W J Musial, G Raczak, J Szachniewicz, J K Wranicz, S Apostolović, S Hinić, V Miloradović, D Simić, G J Milhous, A Oomen, T J Romer, L M van Vijk, P B Adamson, J D Allred, N Amjadi, M M Bahu, A J Bank, A E Berman, M A Bernabei, R S Bhagwat, L Borgatta, A J Buda, R T Cole, J L Collier, S J Compton, O Costantini, M R Costanzo, I M Dauber, M P Donahue, I Dor, G F Egnacyzk, E J Eichhorn, C C Eiswirth, S Emani, G A Ewald, R C Forde-McLean, M D Gelernt, D E Haines, C A Henrikson, J M Herre, B Herweg, L Ilkhanoff, L R Jackson 2nd, A Lala, R Lo, B London, B D Lowes, J A Mackall, V Malhotra, F A McGrew, S Murali, A Natale, K R Nilsson, J Okolo, M V Perez, R S Phang, R Ranjan, M Y Rashtian, M J Ross, S M Samii, T Shinn, M B Shoemaker, S A Strickberger, V N Tholakanahalli, A Tzur, P J Wang, L T Younis

Affiliations

¹ Duke Clinical Research Institute & Duke University Medical Center, Durham, NC (J.P.P.).
² ARCA biopharma, Inc, Westminster, CO (C.D., I.A.C., D.M., M.R.B.).
³ Population Health Research Institute, McMaster University, Hamilton, ON (J.S.H., S.J.C.).
⁴ Ohio State University Medical Center, Columbus (W.T.A.).
⁵ Southlake Regional Health Center, Newmarket, ON (Y.K.).
⁶ University of Colorado, Aurora (R.A., M.R.B.).
⁷ Nebraska Heart Institute, Lincoln (S.K.K.).
⁸ Brigham and Women's Hospital & Harvard Medical School, Boston, MA (W.H.S.).
⁹ Libin Cardiovascular Institute of Alberta, University of Calgary (S.B.W.).
¹⁰ University of Groningen & University Medical Center Groningen, the Netherlands (M.R., D.J.v.V.).
¹¹ University of Minnesota, Minneapolis (I.S.A.).
¹² Montreal Heart Institute, QC (M.W.).
¹³ St. George's University of London, United Kingdom (A.J.C.).
¹⁴ Medtronic, PLC, Minneapolis, MN (P.D.Z.).

PMID: 34270905
DOI: 10.1161/CIRCEP.120.009591

Abstract

[Figure: see text].

Trial registration: ClinicalTrials.gov NCT01970501.

Keywords: atrial fibrillation; atrial flutter; bucindolol; heart failure; metoprolol.

Publication types

Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Adrenergic beta-Antagonists / therapeutic use
Aged
Atrial Fibrillation / etiology
Atrial Fibrillation / genetics
Atrial Fibrillation / prevention & control*
Electrocardiography / drug effects*
Female
Follow-Up Studies
Genotype
Heart Failure / complications
Heart Failure / genetics*
Heart Failure / physiopathology
Humans
Male
Propanolamines / therapeutic use*
Receptors, Adrenergic, beta-1 / drug effects
Receptors, Adrenergic, beta-1 / genetics*
Receptors, Adrenergic, beta-1 / metabolism
Time Factors

Substances

ADRB1 protein, human
Adrenergic beta-Antagonists
Propanolamines
Receptors, Adrenergic, beta-1
bucindolol

Associated data

ClinicalTrials.gov/NCT01970501